Skip to content
MARKETS / BALCAO / INBP
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Integrated Biopharma Inc. INBP

15 fiscal years on record · USD · FY2024 reported · SEC filings only
$54.4M
▲ 8.0% YoY
$808,000
▲ 621.4% YoY
$1.9M
▲ 380.5% YoY
In brief

What this company does

Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company was originally incorporated in the state of Delaware on August 31, 1995 under the name Chem International, Inc., on December 5, 2000, changed its name to Integrated Health Technologies, Inc. and, on January 29, 2003, changed its name to Integrated BioPharma, Inc. The Company’s business segments include: (a) Contract Manufacturing operated by Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers and (b) Other Business Lines which includes the operations of (i) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfillment services, (ii) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC and the holding entity of the Company and (iii) all other inactive subsidiaries of the Company. The Company’s customers are located primarily in the United States and Luxembourg. As of September 23, 2025, we had approximately 153 full time employees, including 117 who are members of the local unit of the Teamsters Union and are covered by a collective bargaining agreement which expires on August 31, 2026.

Written from the business description in INTEGRATED BIOPHARMA INC's annual report to the U.S. Securities and Exchange Commission, filed 23 September 2025. Every sentence was checked against that document before publication.

Growth
USD 54.4M
Revenue, FY2024 · full 15-year series below
Revenue $M Net income $M
FY2024 · Revenue 54.4 · Net income 0.8
25.0M50.0M20102012201420162018202020222024
Compound annual growth
−1.1%
+0.6%
+3.8%
−40.5%
−27.8%
+1.0%
−37.0%
−25.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +0.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
1 cents
of every revenue dollar became profit
Operating margin Net margin
FY2024 · Operating 3.7% · Net 1.5%
5%10%-2%-4%-6%20102012201420162018202020222024
ROE
FY2024 · ROE 4.1%
50%100%20102012201420162018202020222024

Each USD of equity produced 4 cents of profit this year.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF 1.9
2.0M-0.5M-1.0M20102012201420162018202020222024

Total assetsUSD 24.9M
EquityUSD 20.3M
CashUSD 3.6M
Current ratio4.42×

Equity funds 82% of total assets.

The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202420232022202120202019201820172016201520142013201220112010
Revenue $B0.10.10.10.10.10.10.00.00.00.00.00.00.00.00.0
Operating income $B0.00.00.00.00.00.00.00.00.00.00.00.00.0−0.0−0.0
EBITDA $B0.00.00.00.00.00.00.00.00.00.00.00.00.0−0.0−0.0
Income tax $B0.00.00.0−0.0−0.0−0.00.00.0−0.00.00.00.00.00.00.0
Net income $B0.00.0−0.00.00.00.00.00.00.00.00.00.00.0−0.0−0.0
Free cash flow $B0.00.00.00.00.00.0−0.00.00.0−0.0−0.00.0−0.0−0.00.0
EPS, diluted $0.030.000.000.120.250.130.060.020.100.050.020.010.00−0.13−0.11
Dividend / sh $···············
Payout %···············
ROE %4.10.6−0.223.378.6103.2·········
Shares out B0.030.030.030.030.030.030.030.020.020.020.020.020.020.020.02

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 72 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 23 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image